Evolus(EOLS.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Evolus
EOLS.US
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
4.675 T
EOLS.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking78/189
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE245.43%A
    • Profit Margin-14.39%D
    • Gross Margin66.86%A
  • Growth ScoreC
    • Revenue YoY9.56%B
    • Net Profit YoY22.74%B
    • Total Assets YoY3.41%C
    • Net Assets YoY-335.81%E
  • Cash ScoreC
    • Cash Flow Margin84.25%C
    • OCF YoY9.56%B
  • Operating ScoreA
    • Turnover1.39A
  • Debt ScoreE
    • Gearing Ratio113.04%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

    Unusual Whales·
    US
    EOLS
    +1.32%
    Unusual Whales·
    US
    EOLS
    +1.32%

    Evolus (EOLS) Breakeven Q4 EPS Tests Skeptics Of Its Profitability Path

    Simplywall·
    US
    EOLS
    +1.32%
    US
    SBIO
    +1.63%
    US
    FBT
    +0.76%
    Simplywall·
    US
    EOLS
    +1.32%
    US
    SBIO
    +1.63%
    US
    FBT
    +0.76%

    Evolus shares are trading higher after the company reported better-than-expected Q1 sales results.

    benzinga_article·
    US
    EOLS
    +1.32%
    US
    BBH
    +0.22%
    US
    LABU
    +5.30%
    benzinga_article·
    US
    EOLS
    +1.32%
    US
    BBH
    +0.22%
    US
    LABU
    +5.30%

    Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed

    Tip Ranks·
    US
    EOLS
    +1.32%
    US
    IBB
    +0.85%
    US
    BBH
    +0.22%
    Tip Ranks·
    US
    EOLS
    +1.32%
    US
    IBB
    +0.85%
    US
    BBH
    +0.22%

    Evolus Earnings Call Highlights Profitable Growth Path

    Tip Ranks·
    US
    EOLS
    +1.32%
    US
    IBB
    +0.85%
    US
    XBI
    +1.82%
    Tip Ranks·
    US
    EOLS
    +1.32%
    US
    IBB
    +0.85%
    US
    XBI
    +1.82%
    © 2026 Longbridge｜Disclaimer